KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Deferred Taxes (2021 - 2025)

Castle Biosciences (CSTL) has disclosed Deferred Taxes for 5 consecutive years, with -$907000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 60.68% to -$907000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, down 544.54% year-over-year, with the annual reading at -$6.2 million for FY2025, 544.54% down from the prior year.
  • Deferred Taxes hit -$907000.0 in Q4 2025 for Castle Biosciences, down from $116000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $5.2 million in Q3 2024 to a low of -$8.7 million in Q4 2021.
  • Historically, Deferred Taxes has averaged -$1.2 million across 5 years, with a median of -$770000.0 in 2025.
  • Biggest five-year swings in Deferred Taxes: surged 99.57% in 2022 and later crashed 877.54% in 2024.
  • Year by year, Deferred Taxes stood at -$8.7 million in 2021, then soared by 99.57% to -$38000.0 in 2022, then tumbled by 521.05% to -$236000.0 in 2023, then plummeted by 877.54% to -$2.3 million in 2024, then surged by 60.68% to -$907000.0 in 2025.
  • Business Quant data shows Deferred Taxes for CSTL at -$907000.0 in Q4 2025, $116000.0 in Q3 2025, and -$4.7 million in Q2 2025.